11147782

First Jazz Complaint in D. Del. over Avadel's FT218/LUMRYZ. The consolidated action asserted five patents, including U.S. 8,731,963. The court held the '963 claims directed to systems, not methods, and ordered Jazz to request delisting from the Orange Book; on March 7, 2023, the '963 infringement claims and related counterclaims were dismissed by stipulation. Other patents, including U.S. 10,758,488 and 11,147,782, proceeded to a 2024 jury verdict.

Appeal arising from the February 2024 patent trial/injunction phase after the March 4, 2024 verdict. The Federal Circuit issued an opinion on May 6, 2025 reversing/vacating portions of the district court's injunction relating to open-label extensions, new clinical trials, and seeking FDA approval for additional indications. The narrative could not confirm whether any ruling on the '488 patent itself was appealed.

Fourth Jazz complaint/antitrust case involving Jazz's listing of the '963 (REMS) patent and Avadel's Sherman Act counterclaims. Jazz moved to stay pending final resolution of the validity of U.S. Patent No. 11,147,782. Dismissed with prejudice on October 27, 2025 pursuant to settlement.

Avadel's affirmative trade-secrets and inventorship action; Avadel alleged Jazz used confidential information and sought correction of inventorship of certain Jazz patents, including the '782 patent. Dismissed with prejudice on October 27, 2025 pursuant to settlement.

Consolidated Federal Circuit appeal from D. Del. Nos. 1:21-cv-00691-GBW, 1:21-cv-01138-GBW, and 1:21-cv-01594-GBW concerning the permanent injunction in the '782 patent dispute. The Federal Circuit reversed-in-part, vacated-in-part, and remanded on May 6, 2025.